Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Teleconference Memorandum - July 16, 2009



Teleconference Memorandum

 DATE:  July 16, 2009

TIME:  4:15 pm, eastern standard time

SUBJECT:  Hiberix BLA STN 125347—Package Insert

PRODUCT:  Hiberix

SPONSOR:  GlaxoSmithKline (GSK)

CBER Participants:  Karen Farizo

GSK Participants: Elisa Harkins


GSK initiated the call to request clarification on the Indications and Usage Section of the Hiberix package insert. Currently, the package insert states: “HIBERIX is to be used as a booster dose in children who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primary immunization.” GSK inquired whether it would be acceptable to include language that would permit use of HIBERIX in children 15 months through 4 years of age who had not yet completed the primary series with another vaccine (including children who were “partially primed”). CBER indicated that the approval was for booster immunization only, not primary immunization, and that no data had been submitted on use of HIBERIX in children who were “partially primed”. CBER advised GSK that they could submit any proposal for changes to the Indications and Usage Section of the package insert to the BLA. GSK indicated that they did not anticipate doing so, but wanted clarification from CBER to pre-empt questions about usage of HIBERIX. 

Call concluded.

Page Last Updated: 03/23/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English